T1	Outcomes 26 91	health-related quality of life, pain, and skeletal-related events
T2	Outcomes 318 334	overall survival
T3	Outcomes 339 377	radiographic progression-free survival
T4	Outcomes 586 659	health-related quality of life (HRQoL), pain, and skeletal-related events
T5	Outcomes 841 846	HRQoL
T6	Outcomes 987 998	Pain status
T7	Outcomes 1066 1107	Brief Pain Inventory Short Form (BPI-SF).
T8	Outcomes 1112 1142	primary analysis of HRQoL data
T9	Outcomes 1265 1354	change from baseline, percentage improvement, and time to deterioration in HRQoL and pain
T10	Outcomes 1360 1412	proportion of patients with a skeletal-related event
T11	Outcomes 1418 1455	time to first skeletal-related event.
T12	Outcomes 1591 1616	Median treatment duration
T13	Outcomes 1768 1801	significant treatment differences
T14	Outcomes 1893 1935	endpoints and EQ-5D visual analogue scale.
T15	Outcomes 1936 1980	Median time to deterioration in FACT-P total
T16	Outcomes 2290 2312	improvements in FACT-P
T17	Outcomes 2350 2373	[23%] of 790), in EQ-5D
T18	Outcomes 2412 2437	[16%] of 623), and visual
T19	Outcomes 2487 2507	603; all p<0路0001).
T20	Outcomes 2508 2534	Median time to progression
T21	Outcomes 2688 2715	CI 0路53-0路74]; p<0路0001)
T22	Outcomes 3038 3067	placebo group had experienced
T23	Outcomes 3070 3108	skeletal-related event by data cutoff.
T24	Outcomes 3109 3129	Median time to first
T25	Outcomes 3333 3359	INTERPRETATION In addition
T26	Outcomes 3411 3493	enzalutamide significantly improves patient-related outcomes and delays occurrence
